P-gp、GST-π、TopoⅡ及LRP在胃癌组织中的表达及其临床意义

Expression of P-glycoprotein,Glutathione-S-transferase π,Topoisomerase Ⅱand Lung resistance protein and its clinical significance in Gastric Carcinoma

目的:探讨P-糖蛋白(P-glycoprotein,P-gp)、谷胱甘肽-S-转移酶(Glutathione-S-transferaseπ,GST-π)、DNA拓扑异构酶Ⅱα(TopoisomeraseⅡα,TopoⅡ)和肺耐药蛋白LRP(Lung resistance protein,LRP)在胃癌组织中的表达及其临床意义。方法:采用免疫组化法和组织芯片技术检测78例胃癌中癌组织和癌旁正常组织中P-gp、GST-π、TopoⅡ及LRP的表达。结果:78例胃癌组织中,癌组织与相应癌旁正常组织中P-gp的阳性表达率分别为83.3%和12.8%,GST-π为64.1%和29.5%,TopoⅡ为76.9%和11.5%,LRP为89.7%和11.5%,癌组织中P-gp、GST-π、TopoⅡ和LRP的表达均明显高于癌旁正常组织(P<0.05)。P-gp和TopoⅡ的表达与胃癌组织的分化程度相关,GST-π的表达与淋巴结转移有关。结论:P-gp、GST-π、TopoⅡ及LRP联合作用可能是介导胃癌多药耐药的主要机制,检测P-gp、GST-π、TopoⅡ及LRP的表达水平对胃癌的化疗药物方案选择及预后判断具有一定的参考意义。

Objective： Purpose To evaluate the expression of P-gp, GST-π, Topo Ⅱ, LRP and its clinical significance in gastric carcinoma. Methods： Using the immunohistochemical method on the tissue micmarray, the expression of P-gp, GST-π,Topo Ⅱ and LRP were detected in the 78 cases of gastric carcinoma. Results： The positive rate of P-gp, Topo Ⅱ, GST-πand LRP expression in the cancer tissues was 83.3% （65/78）, 64. 1% （50/78）, 64. 1% （50/78） and 89.7% （70/78）, respectively, which aws siginificantly higher than that in the adjacent normal tissues （all P 〈 0.05 ）. Moreover, the expression of P-gp and Topo Ⅱ were associated with the degrees of differentiation. The expression of GST-π was related with the lymph node metastasis. Conclusion： The combined effect of P - gp, GST-π, Top Ⅱ and LRP may be an key rea- son for multidrug resistance of patients with gastric carcinoma, thus they can be used as considerable biomarkers to evaluate the choice of drugs and plans in gastric carcinomas chemotherapy.